An 12-week, Prospective, Interventional, Single-arm, Multi-centre, Phase III Study to Examine the Efficacy and Safety of Flutiform K-haler in Asthma Patients Who Are Not Adequately Controlled by Mid-doseICS/LABA DPI Treatment
Latest Information Update: 27 Jan 2021
At a glance
- Drugs Formoterol/fluticasone propionate (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms SWIFT
- Sponsors Mundipharma International
- 21 Jan 2021 Status changed from not yet recruiting to discontinued.
- 15 Oct 2019 New trial record